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Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that 
can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on 
oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune 
functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically 
investigated, however. 
Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective 
based on open literature search of the topic.  
Results: These target specific drugs appear to have less drug interactions than earlier immunomodulating medi-
cines but have nevertheless potential side effects such as activating latent infections. There are some data showing 
that the new immunomodulatory drugs may also have a role in the treatment of certain oral diseases such as lichen 
planus or ameliorating symptoms in Sjögren s´ syndrome, but the results have not been overly promising. 
Conclusions: In general, data are sparse of the effect of these new drugs vs. oral diseases and there are no properly 
powered randomized controlled trials published on this topic. 
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Introduction
Immunomodulatory drugs modify the response of the 
immune system by increasing (immunostimulators) or 
decreasing (immunosuppressives) the production of se-
rum antibodies (1). Immunostimulators are prescribed 
to enhance the immune response against infectious dis-
eases, tumours, primary or secondary immunodeficien-
cy, and alterations in antibody transfer, among others 
(2). Immunosuppressive drugs are used to reduce the 
immune response against transplanted organs and to 
treat autoimmune diseases such as pemphigus, lupus, 
or allergies (3,4). In this review article we describe the 
concept and role of immunomodulation in oral medi-
cine and dentistry with emphasis on new immunomod-
ulatory drugs. 
Material and Methods
The review is based on open PubMed search up to June 
2012 using the following key words: immunomodulato-
ry drugs and oral health (17 hits), oral diseases (40 hits), 
dental (12 hits), lichen planus (4 hits), pemphigus vul-
garis (3 hits), pemphigoid (8 hits), erythema multiforme 
(2 hits), Stevens-Johnson syndrome (2 hits), systemic 
lupus erythematosus (31 hits), Sjögrens s´ syndrome (11 
hits), autoimmune disease (426 hits). Relevant articles 
were then investigated. 
This work was made into an investigation Project from 




-Mechanisms of action of immunomodulators
Immunomodulators act at different levels of the im-
mune system. Therefore different kinds of drugs have 
been developed that selectively either inhibit or inten-
sify the specific populations and subpopulations of im-
mune responsive cells, i.e. lymphocytes, macrophages, 
neutrophils, natural killer (NK) cells, and cytotoxic 
T lymphocytes (CTL). Immunomodulators affect the 
cells producing soluble mediators such as cytokines (5). 
Thus, in immunotherapy the immune system is targeted 
in order to help the healing of a given disease. As an 
example, the inflammatory processes involved in rheu-
matoid arthritis are shown in figure 1.
Immunosuppressants inhibit the immune response in 
organ transplantation and autoimmune diseases, where-
as immunostimulants increase the immune response in 
infections, immunodeficiency (for example AIDS) and 
cancers. The term immunomodulation is used rather 
than immunostimulator for a substance that causes 
measurable alterations in immune function. Their ac-



























Fig. 1. Inflammation in the Rheumatoid Joint. Exogenous antigens are taken up by antigen-presenting cells (APCs). These 
include: phagocytic cells like dendritic cells and macrophages and, B lymphocytes (B cells). Cytokines are produced by 
stimulation of polymorphonuclear leukocytes and macrophages. 
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Specific-action immunomodulators affect the immune 
system of the cells according to the presence of a par-
ticular antigen or immunogen, with selective specificity 
for immune response. Immunomodulation is selective 
when the stimulation translates into an immunoreaction 
to one or several antigens, as in the case of adjuvants or 
therapeutic vaccines. Immunological adjuvants enhance 
the effect of vaccines with synthetic antigens, including 
new-generation antigens. These agents are also used in 
experimental immunization to obtain polyclonal antise-
rums and monoclonal antibodies for utilization in vac-
cines (5).
Non-specific-action immunomodulators are used to 
stimulate or suppress the immune response, without di-
recting the activity of stimulated cells to a specific an-
tigen. They are divided into three types:  type I, acting 
on normal immune system; type II, acting on immu-
nosuppressed immune system; and type III, acting on 
functionally normal and immunosuppressed immune 
system (5).
Autoimmune diseases present with varying symptoms 
and signs depending on the type of disease and on the in-
dividual affected. Thus, for example, skin and joints can 
be involved in lupus, whereas skin, kidney, and lungs 
can be involved in other autoimmune diseases. Immu-
nosuppressants are among the most effective drugs also 
in the treatment of inflammatory bowel diseases. For 
example, corticosteroids are used in Crohn’s disease to 
avoid reactivation and post-surgical relapse (6). 
-Therapeutic action of different immunomodulators 
Tables 1,2 give the immunostimulating and immuno-
suppresssant drugs, respectively, and their pharmaco-
logical effects. Immunomodulators are used when the 
immune system is inadequate to reduce an infection or 
combating cancer, for example (6). But as can see from 
the tables, there are a number of different agents with 
Table 1.  Immunostimulators.
FAMILY DRUG PHARMACOLOGICAL EFFECT




Activation of macrophages (APC), NK cells, and B lymphocytes
Muramyl dipeptide (MDP) 
L-MTP-PE
Activation of macrophages (APC and phagocytosis)
Activation of macrophages (APC and phagocytosis)
Lipopolysaccharides 
(LPS)
Activation of macrophages and B lymphocytes
Propionibacterium species APC, phagocytosis, Activation of Tc and B lymphocytes
Glucan Phagocytosis
Thymic factors Thymosins Maturation of thymocytes into T lymphocytes 
Synthetic drugs Levamisole
Isoprinosine
Maturation and activation of T lymphocytes, phagocytosis, and 
chemotaxis 
Proliferation of T lymphocytes; activation of Th, Tc, NK,
phagocytosis and chemotaxis
Polyclonal antibodies Specific antibodies Triggering effector phase of specific immunity against various an-
tigens
Recombinant cytokines Interleukin 2 (IL-2) Activation of lymphocytes Th (proliferation), 
Interleukin 1 (IL-1) Tc (lysis), and B
Interleukin 12 (IL-12) Activation of Th lymphocytes
Interferon gamma (IFN-γ) Proliferation of monocytes
Activation of macrophages, lymphocytes, and NK cells, increase in 
expression of     MHC II
Monoclonal antibodies Specific antibodies Triggering effector phase of specific immunity against antigen
(e.g., tumor)
Vaccines Antigens Triggering of specific immunity (phases of recognition, activation, 
and effector)
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immunomodulatory effects used for a variety of thera-
peutic purposes. Of the new generation immunomodu-
lators, tumour necrosis factor (TNF) antagonists are spe-
cially mentioned here. TNF-α, an inflammatory cytokine 
released by activated monocytes, macrophages, and T 
lymphocytes, promotes inflammatory responses that are 
important in the pathogenesis of rheumatoid arthritis. Pa-
tients with rheumatoid arthritis have high concentrations 
of TNF-α in their synovial fluid (7). Hence the TNF an-
tagonists are widely used in rheumatic diseases.
-Adverse effects
By acting on the immune system, all these drugs may 
increase the risk of infection. Although usually mild 
and risk-free, the infections can also be severe, includ-
ing those caused by opportunistic agents (8). Reactiva-
tion of latent tuberculosis is also a known untoward ef-
fect particularly reported in connection with the new 
generation immunomodulatory drugs (8). In general, 
adverse effects impair the quality of life of the immu-
nosuppressed patient, and pharmacological effects rep-
resent the leading cause of death in transplant patients, 
for example (9). Interestingly, we could not find any 
literature regarding eventual activation of periodontal 
disease, for example, in patients taking immunomodu-
latory drugs. In theory such an untoward development 
might be possible (10). 
Azathioprine and 6-mercaptopurine can cause medullar 
suppression and a periodical blood count is mandatory 
for patients receiving these drugs. It is also recommend-
ed to take gastric protectors to avoid possible gastric ir-
ritation. Other adverse effects include pancreatitis, hep-
atitis, myalgia, and dizziness, among others. Because 
of adverse effects azathioprine needs to be withdrawn 
in 15-30% of patients (11). Adverse effects are observed 
in 10% of patients taking 50mg/day of azathioprine and 
can be divided into dose-independent or idiosyncratic 
effects (rash, fever, alopecia, diarrhoea, and pancreati-
tis) and dose-dependent or toxic effects (nausea, myelo-
toxicity and hepatotoxicity) (12,13). Around 5% of pa-
tients show elevated transaminase levels (14) and there 
have been reports of severe bacterial infections, tuber-
culosis, atypical mycobacterial infection, aspergillosis, 
histoplasmosis, coccidioidomycosis, listeriosis, Pneu-
mocystis carinii pneumonia, cryptococcal infections, 
cytomegalovirus, and other infections (8). These infec-
tions are common among patients over 65 years old. 
Methotrexate, which can be administered intramuscu-
larly or intravenously but also orally, may cause flu-like 
syndrome, nausea, vomiting, fatigue, diarrhoea, med-
ullar toxicity, and detrimental effects on the lung or liv-
er. The toxicity of methotrexate is dose-dependent and 
therefore influenced by factors that affect its absorption, 
distribution, and excretion (15). High doses produce 
acute and transient elevations of aspartate transferase 
(AST) and are associated with myelosuppression, mu-
cocutaneous reactions, pneumonitis, and gastrointes-
tinal disturbances (anorexia, nausea and diarrhoea). 
Prolonged low doses, as in the treatment of psoriasis, 
rheumatoid arthritis, inflammatory bowel disease, and 
liver disorders, produce abnormalities ranging from 
analytical alterations to chronic liver disease, fibrosis, 
and cirrhosis (15). Methotrexate is contraindicated in 
women who are pregnant or breast feeding.
Cyclosporine is administered orally or intravenously. 
Adverse effects include hypertension, nephropathy, 
convulsions, hyperkalemia, shaking, and hepatitis, 
among others (11). The most common side effects de-
rive from cyclosporine nephrotoxicity, including hyper-
tension, neurotoxicity, hirsutism, epilepsy, headache, 
paresthesia, and gingival hyperplasia. In clinical prac-
Table 2.  Immunosuppressants.
FAMILY DRUG PHARMACOLOGICAL EFFECT
Drugs that bind to 
immunophilins 
Cyclosporine A, Tacrolimus and Sirolimus Inhibition gene transcription of cytokines 
(e.g., IL-2) in T lymphocytes (blocking 
their proliferation), Inhibition of cytokines 
of T lymphocytes 
Glucocorticoids Prednisone  and dexamethasone Inhibition of transcription of cytokines into 
T lymphocytes and macrophages
Cytostatics Azathioprine, 
Cyclophosphamide, Mophetil mycopheno-
late  and Leflunomide
Inhibition of cell proliferation, Inhibition 
of proliferation of T and B lymphocytes, 
Inhibition of cell proliferation
Antilymphocyte antibodies Polyclonal antibodies
Anti-thymocytes
Triggering effector phase of specific im-
munity against lymphocytes
Monoclonal antibodies Muromonab (OKT3)
Anti-cytokines and anti-receptors 
Destruction of CD3+ cells (T 
lymphocytes),Neutralization  or destruc-
tion of molecules of the immune system
Hyposensitization Allergens Reversal of response from type IgE to IgC 
(from Th2 to Th1), Reduction in reactivity 
to allergen
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tice, cyclosporine-induced liver damage is character-
ized by increased serum alkaline phosphatase levels 
and a mild elevation of aminotransferases and conju-
gated bilirubin. These biochemical abnormalities usu-
ally appear between the second week and third month 
after initiation of treatment and tend to normalize after 
reducing the dose (15). Cyclosporine use during preg-
nancy is not recommended. Mycophenolate and tac-
rolimus are alternatives to cyclosporine but these drugs 
may increase the risk of diabetes (16). Reported adverse 
effects of tacrolimus are local irritation, tingling, burn-
ing sensation, altered taste, nausea, headache, and mod-
erate diaorrhea, even when drug absorption is within 
the therapeutic range of absorption according to urine, 
blood, and liver analyses; however, tacrolimus hepato-
toxicity is relatively uncommon (17). 
TNF antagonists are monoclonal antibodies such as 
infliximab, adalimumab, certolizumab pegol, and goli-
mumab, or circulating receptor fusion protein such as 
etanercept. The drugs may activate tuberculosis most 
often due to the reactivation of latent infection and usu-
ally within the first two to five months of treatment. 
Headache, nausea, dizziness, blood glucose changes, 
epistaxis, infection, and decreased platelets and white 
blood cells have also been described as side effects of 
the TNF antagonists. But also lymphoma has been re-
ported in association with TNF antagonists, although a 
causal relationship is controversial (7).  
Finally, corticosteroids widely used for a number of in-
dications need to be mentioned. The most severe acute 
adverse effect from the use of corticosteroids is adrenal 
crisis due to their abrupt withdrawal after prolonged ad-
ministration. Other reported side effects are hyperten-
sion, hypercholesterolemia, glucose intolerance, insom-
nia, emotional lability, psychotic disorders, cataract, 
osteopenia with vertebral compression, diabetes, and 
cosmetic changes, such as “moon face” (Cushing syn-
drome), “buffalo hump”, acne and hirsutism. These side 
effects appear in 80% of patients after 2 years of treat-
ment and resolve on withdrawal of the corticosteroid. 
With regard to effects on the liver, high doses of gluco-
corticoids can produce hepatic steatosis by promoting 
the mobilization and redistribution of fat, increasing 
plasma free fatty acids by inhibiting the esterification 
of fatty acids in the liver (18). 
-Drug interactions
A drug interaction is the modification of the pharmaco-
dynamic and/or the pharmacokinetics of a drug as a re-
sult of the joint processing of other medications or foods 
or habits such as snuff use or frequent alcohol consump-
tion. For example, leflunomide may increase the anti-
coagulant activity of warfarin (19,20). The spectrum of 
drug interactions ranges widely from those without any 
clinical relevance to those that produce a severe adverse 
reaction in the patient. 
In general, drugs used by dental practitioner, such as 
antibiotics, pain killers and local anaesthetics, are well 
tolerated with the new biological medicines. Most of 
the drugs undergo some degree of biotransformation 
before elimination. It has been well established that 
the biological target for the vast majority of these drug 
metabolic interactions is in the cytochrome P450 sys-
tem (CYP) (21). Schmitt et al. have shown that tocili-
zumab, an interleukin-6 receptor inhibitor, may reverse 
IL-6-induced suppression of CYP3A4 activity and thus 
“normalizes” CYP3A4 activity to a level similar to that 
in healthy persons (22).  This finding showed the impor-
tance of caution with patients taking tocilizumab and 
simvastatin, and thus with any other CYP3A4 metabo-
lized drugs. Special interest to dental treatment are the 
CYP3A4 substrates, such as the local anaesthetic lido-
caine, and the popular anxiolytics midazolam and di-
azepam, and CYP3A4 inhibitors, such as erythromycin 
and clarithtromycin and macrolide antibiotics in gen-
eral, and azole antifungal drugs in particular (21,23). 
Apart from the increased drug concentrations observed 
with simultaneous use of the certain antifungal agents 
and immunomodulating drugs, however, there is no evi-
dence for interactions with the drugs commonly used 
in the dental practice and the novel biologic agents dis-
cussed here. 
-Impact of immonumodulation on oral diseases
Autoimmune diseases frequently involve the oral mu-
cosa which often is the first site of manifestation (24). 
A detailed clinical examination of the oral mucosa of an 
asymptomatic patient can be the best opportunity for 
the early diagnosis and treatment of these autoimmune 
diseases, allowing control over their spread to the skin 
and/or other body organs (25). Table 3 lists the impor-
tant autoimmune diseases with oral manifestations.
Novel therapies based on pathogenesis 
Interest in B-cell–targeted therapies has increased 
worldwide following recent convincing evidence that 
innate immunity, most notably mediated by INF signal-
ling, plays a role in initial B-cell activation. Numerous 
drugs under current evaluation, including epratuzum-
ab, a monoclonal antibody directed at the CD22 B-cell 
surface antigen, which may preferentially target auto 
reactive B cells, target the B lymphocyte pathogenic 
axis (see Fig. 1). Baminercept, a lymphocytotoxin-beta 
receptor fusion protein, which along with BAFF sup-
ports the formation of germinal centers within salivary 
glands, is another molecule of interest for autoimmune 
diseases (26).  
Particular promise has been shown by belimumab, a 
monoclonal antibody that specifically targets the BAFF 
receptor and may disrupt the cycle of B-cell activation 
and antibody production. Belimumab appears to be ef-
fective for systemic lupus erythematosus (SLE) and is 
undergoing early stage development for SS (27). 
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Potential new cytokine therapeutic targets were re-
cently suggested by data to implicate proinflammatory 
Th17 cells in SS. IL-17 and IL-23, as well as the related 
pro-inflammatory cytokines IL-12 and IL-6, are promi-
nently expressed in SS salivary gland tissue (26). 
Rituximab was the first B-cell–targeting therapy to be 
evaluated in SS. Rituximab is a mouse-human (chimer-
ic) antibody directed against the CD20 cell surface an-
tigen present on B cells. It was introduced as treatment 
for primary lymphoma and results in the depletion of 
circulating B cells. The usefulness of rituximab to treat 
lymphoma and knowledge of the role played by B-cell 
hyperactivity in the systemic manifestations of SS led 
to its proposal for therapeutic application in SS some 
years ago (28). The use of B-cell–depleting therapies 
in SS is supported by evidence that rituximab treat-
ment depletes B cells in parotid gland tissue and in the 
peripheral blood, as well as it restores normal T-cell 
regulatory function, reduces glandular inflammation, 
and improves the function and regression of lympho-
epithelial lesions that predispose to the development of 
lymphoma (29). 
Rituximab was found to improve subjective sicca symp-
toms, fatigue, and quality-of-life (29). Two small ran-
domized double-blind controlled studies have demon-
strated its efficacy and safety in SS (30,31). The evidence 
suggests that rituximab is effective for extra-glandular 
manifestations of SS (29-31). 
In contrast to B-cell inhibitor, rituximab as an anti-
TNG agent has not shown any evidence of efficacy in 
SS treatment (32). Similar results were detected with 
another anti-TNF-alpha antibody (etanercept, inflixi-
mab. However, it seems that the new immonumodulato-
ry drugs in general have shown disappointing results in 
treatment of SS as reviewed by Carsons (4). The author 
stresses the need for properly powered and controlled 
studies on the topic. 
Etanercept, efalizumab and alefacept were used in treat-
ment of oral lichen planus (OLP). Etanercept inhibits 
binding of TNF-alpha to cell surface TNF receptors and 
thus prevents TNF-mediated cellular responses. It has 
been shown to relief OLP symptoms in two weeks after 
commencement of therapy and clinical improvement in 
four weeks (33). Efalizumab and alefacept, both T-cell 
inhibitors, have also been reported to be successful in 
the treatment of OLP (34). Reason for the efficacy of 
these agents is thought to be due to increased activation 
of T-cells and proliferation. In contrast to this finding, 
Asarch et al. demonstrated lichen planus-like eruptions 
after infliximab and adalimumab therapy for psoriasis 
(35). They suggested that TNF-alpha inhibition may 
precipitate lichenoid reactions through disruption of 
delicate balance between TNF-alpha and interferon-
alpha in susceptible patients. Similar result was found 
with a patient with Crohn’s disease after certolizumab 
pegol treatment (36). Hence the issue remains contro-
versial and more studies are called for further evidence 
if or not these drugs have a role in the treatment of li-
chen planus. 
In SLE, TNF is a proinflammatory and regulatory cy-
tokine with divergent effector on the immune system. 
Thus, TNF inhibition by infliximab and etanercept are 
of interest in SLE treatment. It has been shown that in a 
short-term therapy, infliximab is effective and relatively 
safe in SLE treatment but in the long-term therapy inf-
liximab, however, was associated with severe infections 
and potentially also lymphomas are of concern if thera-
py is continued (37,38). 
B-cell activation and autoantibodies are characterized 
in SLE. Thus, rituximab as an anti-CD20 antibody is of 
interest in evaluating its effectiveness in SLE treatment. 
Results have indicated that rituximab was indeed effec-
tive in SLE, and clinical responses were supported by 
close correlation with B cell numbers (39,40). Moreo-
ver, SLE is known as a highly heterogeneous disease. 
This might explain why not all patient show response 
with rituximab treatment while with abatacept, a T cell 
inhibitor, the results were promising (41-43). However, 
rituximab is considered as the first-choice biological 
agent in patients with SLE (42). 
Interleukin-6 (IL-6) is a key proinflammatory cytokine 
and the serum levels of IL-6 are elevated with SLE pa-
                DISEASE PRINCIPAL MANIFESTATION REFERENCE 
Lichen planus Mucosal manifestation Lopez-Jornet P et al, 2010 (17) 
Pemphigus vulgaris Blisters Arisawa E et al, 2008 (25) 
Cicatric pemphigoid Blisters Chan, 2012 (3) 
Erythema multiforme Erytroplakia, cocardic lesions  
Stevens Johnson syndrome Exfoliative lesions  
Systemic lupus erythematosus Erythematosus on mucosa Uppal SS et al, 2009 (38) 
Sjögren ´s syndrome Xerostomia Bowman, 2012 (28) 
Linear IgA dermatosis Vesicles, ulcerations, erosion Del Valle et al, 2003 (46) 
Table 3.  Oral manifestations autoimmune diseases.
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tients (44). Inhibition of IL-6 by tocilizumab has shown 
promising responses in clinical and serologic manifesta-
tions of lupus activity in patients with SLE (45). Never-
theless, Illei et al. found developing dose-related neutro-
penia and high rates of infections in almost all patients 
in their study with tocilizumab treatment (45,46). Thus, 
further studies are needed with IL-6 receptor inhibition 
and SLE.  The future use of these drugs in oral medici-
ne remains open (47). Table 4 summarizes the biological 
drugs used in the treatment of autoimmune diseases.
Conclusion
We have briefly reviewed current knowledge about the 
new immunomodulatory drugs from the oral health 
perspective. The data available show that these drugs 
appear safe as regards possible interactions with com-
monly used medicines in dental practice, such as an-
tibiotics, pain killers and local anaesthetics. However, 
drug interactions may occur with some antifungal 
agents. The interpretation and evaluation of potential 
adverse effects and drug interactions of patients has 
been described as a daily challenge for dentists in gen-
eral and alertness is called for with the introduction of 
new drugs and drug categories. Another area of inter-
est here is the use of the new immunomodulatory drugs 
in treatment of autoimmune diseases with oral mani-
festations. These include diseases such as Sjögren s´ 
syndrome and oral lichen planus. So far, however, data 
are sparse to give any clinical guidelines and properly 
powered randomized controlled trials are needed for 
scientific evidence. 
TARGET DRUG ORAL HEALTH ASPECT 
TNF alpha inhibition Infliximab Increased liability to infections 
 Etanercept Increased liability to infections 
 Adalimumab Increased liability to infections 
 Certolizumab pegol Increased liability to infections 
 Golimumab Increased liability to infections 
T-cell inhibition Abatacept Increased liability to infections 
B-cell inhibition Rituximab Increased liability to infections 
 Belimumab Increased liability to infections 
IL-1 receptor inhibition Anakinra Increased liability to infections 
IL-6 receptor inhibition Tocilizumab Increased liability to infections 
Table 4. Biologic agents in the treatment of autoimmune diseases.
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